Atopic Dermatitis CD56+ NK Cells

About Atopic Dermatitis CD56+ NK Cells

Atopic Dermatitis CD56+ NK Cells for Allergy and Inflammation Research

Atopic Dermatitis CD56+ NK Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with atopic dermatitis. These CD56+ CD3− natural killer cells reflect disease-associated innate immune alterations and support studies of immune surveillance, Th2-skewed inflammation, and cytotoxicity.

NK Cells in Atopic Dermatitis

Atopic dermatitis is a chronic, relapsing inflammatory skin disease driven by epidermal barrier dysfunction and type 2 (Th2) immune skewing — not by autoimmunity. The IL-4/IL-13 axis underlies the current generation of biologics, and NK cells are increasingly recognised as participants rather than bystanders:

• Reduced circulating NK cell numbers and impaired cytotoxicity, reported consistently in moderate-to-severe disease
• Type 2 cytokine skewing — a subset of NK cells produces IL-5 and IL-13, contributing directly to the Th2 milieu rather than counterbalancing it
• Proposed regulatory role — reduced NK function has been linked to failure to restrain type 2 inflammation, making NK deficiency a candidate mechanism rather than an epiphenomenon
• Susceptibility to cutaneous viral infection — impaired NK surveillance is one proposed contributor to eczema herpeticum and increased S. aureus colonisation
• Treatment effects — dupilumab and JAK inhibitors measurably shift the innate compartment, so treatment status is essential context

Donor Stratification Available

• Disease severity — EASI, SCORAD, or IGA scores where recorded
• Total and allergen-specific IgE where tested
• Atopic comorbidities — asthma, allergic rhinitis, food allergy
• Treatment status — topical-only, or on dupilumab, JAK inhibitor, or systemic immunosuppressant
• Flare status — active flare vs quiescent disease
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD56+ enriched NK cells
• Isolated from clinically diagnosed atopic dermatitis donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of atopic dermatitis
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• NK cell phenotype and function studies in atopic dermatitis
• Type 2 inflammation and IL-4/IL-13 axis research
• Cytotoxicity, degranulation, and CD56-bright/dim subset analysis
• Biologic and JAK inhibitor mechanism-of-action research
• Cutaneous antiviral and antibacterial surveillance studies
• Single-cell analysis and biomarker identification
• Preclinical immunotherapy development

Other Atopic Dermatitis Specimen Types

Matched material from atopic dermatitis donors is available as AD CD19+ B cells, PBMC, serum, plasma, and skin punch biopsy for lesional tissue. Related atopic cohorts include allergy serum and chronic spontaneous urticaria.

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Atopic Dermatitis CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD56+ NK cells collection.